HRP20210375T1 - Virus ljudske imunodeficijencije neutraliziranja antitijela i postupci njegova korištenja - Google Patents

Virus ljudske imunodeficijencije neutraliziranja antitijela i postupci njegova korištenja Download PDF

Info

Publication number
HRP20210375T1
HRP20210375T1 HRP20210375TT HRP20210375T HRP20210375T1 HR P20210375 T1 HRP20210375 T1 HR P20210375T1 HR P20210375T T HRP20210375T T HR P20210375TT HR P20210375 T HRP20210375 T HR P20210375T HR P20210375 T1 HRP20210375 T1 HR P20210375T1
Authority
HR
Croatia
Prior art keywords
antibody
antigen
hiv
binding fragment
hiv antibody
Prior art date
Application number
HRP20210375TT
Other languages
English (en)
Inventor
Johannes SCHEID
Michel Nussenzweig
Pamela J. Bjorkman
Ron DISKIN
Original Assignee
The Rockefeller University
California Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Rockefeller University, California Institute Of Technology filed Critical The Rockefeller University
Publication of HRP20210375T1 publication Critical patent/HRP20210375T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (11)

1. Izolirano ljudsko anti-HIV antitijelo ili njegov fragment koji veže antigen, sastoji se od teškog lanca koji sadrži aminokiselinsku sekvencu QVQLLQSGAAVTKPGASVRVSCEASGYNIRDYFIHWWRQAPGQGLQWVGWINPKTGQPNNPRQFQGRVSLTRHASWDFDTFSFYMDLKALRSDDTAVYFCARQRSDYWDFDV i lakog lanca koji sadrži aminokiselinsku sekvencu [image]
2. Izolirano ljudsko anti-HIV antitijelo ili fragment koji veže antigen prema zahtjevu 1 sadrži aminokiselinsku sekvencu SEQ ID NO: 387 i aminokiselinsku sekvencu SEQ ID NO: 558.
3. Pripravak koji sadrži izolirano anti-HIV antitijelo ili fragment koji veže antigen prema bilo kojem od zahtjeva 1-2.
4. Molekula nukleinske kiseline koja kodira izolirano anti-HIV antitijelo ili fragment koji veže antigen prema bilo kojem od zahtjeva 1-2.
5. Vektor koji sadrži molekulu nukleinske kiseline prema zahtjevu 4.
6. Stanica koja sadrži vektor prema zahtjevu 5.
7. Farmaceutski pripravak koji sadrži najmanje jedno antitijelo prema bilo kojem od zahtjeva 1-2 ili njegov fragment koji veže antigen i farmaceutski prihvatljiv nosač.
8. Postupak za izradu anti-HIV antitijela ili njegovog fragmenta koji veže antigen prema bilo kojem od zahtjeva 1-2, navedeni postupak obuhvaća uzgoj stanice koja sadrži vektor koji sadrži nukleinsku kiselinu koja kodira teški i laki lanac navedenog antitijela pod uvjetima u kojima se nukleinska kiselina eksprimira, i izolira navedeno anti-HIV antitijelo ili njegov fragment.
9. Postupak za otkrivanje anti-HIV antitijela prema bilo kojem od zahtjeva 1-2 kod pacijenta, navedeni postupak obuhvaća pružanje biološkog uzorka dobivenog od pacijenta i ispitivanje biološkog uzorka na prisutnost anti-HIV antitijela ili stanice koja sadrži barem jedan od DNA ili mRNA koji kodiraju antitijelo.
10. Terapeutski učinkovita količina najmanje jednog anti-HIV antitijela ili fragmenta koji veže antigen prema bilo kojem od zahtjeva 1-2 ili barem jednog anti-HIV antitijela, ili njegovog fragmenta, načinjena postupkom prema zahtjevu 8, za uporabu u prevenciji ili liječenju HIV infekcije ili bolesti povezane s HIV-om.
11. Terapeutski učinkovita količina antitijela ili fragmenta koji veže antigen za uporabu prema zahtjevu 10, za primjenu s drugim terapijskim sredstvom, pri čemu je navedeno drugo terapijsko sredstvo izborno antivirusno sredstvo.
HRP20210375TT 2011-05-17 2021-03-03 Virus ljudske imunodeficijencije neutraliziranja antitijela i postupci njegova korištenja HRP20210375T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486960P 2011-05-17 2011-05-17
PCT/US2012/038400 WO2012158948A1 (en) 2011-05-17 2012-05-17 Human immunodeficiency virus neutralizing antibodies adn methods of use thereof
EP12785929.6A EP2710033B1 (en) 2011-05-17 2012-05-17 Human immunodeficiency virus neutralizing antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
HRP20210375T1 true HRP20210375T1 (hr) 2021-07-09

Family

ID=47177348

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210375TT HRP20210375T1 (hr) 2011-05-17 2021-03-03 Virus ljudske imunodeficijencije neutraliziranja antitijela i postupci njegova korištenja

Country Status (20)

Country Link
US (4) US9783594B2 (hr)
EP (2) EP2710033B1 (hr)
JP (5) JP6323718B2 (hr)
CN (4) CN116948019A (hr)
AU (5) AU2012255266B2 (hr)
BR (1) BR112013029550A2 (hr)
CA (1) CA2836468C (hr)
CY (1) CY1124043T1 (hr)
DK (1) DK2710033T3 (hr)
EA (2) EA201990685A1 (hr)
ES (1) ES2895523T3 (hr)
HR (1) HRP20210375T1 (hr)
HU (1) HUE053545T2 (hr)
IL (3) IL295205A (hr)
LT (1) LT2710033T (hr)
MX (1) MX358099B (hr)
PL (1) PL2710033T3 (hr)
PT (1) PT2710033T (hr)
SI (1) SI2710033T1 (hr)
WO (1) WO2012158948A1 (hr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013029550A2 (pt) * 2011-05-17 2022-04-19 California Inst Of Techn Anticorpos neutralizantes de vírus de imunodeficiência humana e métodos de uso dos mesmos
US9890207B2 (en) 2011-07-25 2018-02-13 California Institute Of Technology Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
US9493549B2 (en) 2011-07-25 2016-11-15 The Rockefeller University Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
CN104271597B (zh) 2011-12-08 2018-05-25 美国政府(由卫生和人类服务部的部长所代表) Hiv-1的中和抗体及其用途
WO2013192589A1 (en) 2012-06-21 2013-12-27 California Institute Of Technology Antibodies targeting hiv escape mutants
US10308707B2 (en) * 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
US10421803B2 (en) 2014-01-31 2019-09-24 The Rockefeller University Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits
WO2016014484A1 (en) * 2014-07-21 2016-01-28 The Rockefeller University Combination of broadly neutralizing hiv antibodies and viral inducers
MX2017004213A (es) * 2014-09-30 2017-07-19 Neurimmune Holding Ag Anticuerpo anti-repeticiones de dipeptido (dpr) derivados de humano.
WO2016062988A1 (en) * 2014-10-22 2016-04-28 Crescendo Biologics Limited Vh scaffold
CN104697830B (zh) * 2015-02-10 2018-06-15 深圳市新产业生物医学工程股份有限公司 用于hiv检测的酸性处理剂、样本预处理方法、试剂盒及检测方法
US10562960B2 (en) 2015-03-20 2020-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to gp120 and their use
PL3365366T3 (pl) * 2015-10-25 2022-01-31 Sanofi Trójspecyficzne i/lub trójwalentne białka wiążące do zapobiegania lub leczenia zakażenia HIV
US11236152B2 (en) 2015-11-03 2022-02-01 The United States of America, as represented by the Sectetary, Department of Health and Human Services Neutralizing antibodies to HIV-1 GP41 and their use
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
CA3016352A1 (en) 2016-03-03 2017-09-08 Duke University Compositions and methods for inducing hiv-1 antibodies
EP3443006B1 (en) 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
RS64771B1 (sr) 2016-04-13 2023-11-30 Sanofi Sa Trispecifični i/ili trovalentni vezujući proteini
CN105968200B (zh) * 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-l1人源化单克隆抗体及其应用
US11161895B2 (en) * 2016-10-03 2021-11-02 Duke University Methods to identify immunogens by targeting improbable mutations
WO2018075564A1 (en) 2016-10-17 2018-04-26 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
US11325966B2 (en) 2016-12-27 2022-05-10 The Rockefeller University Broadly neutralizing anti-HIV-1 antibodies and methods of use thereof
WO2018169926A1 (en) * 2017-03-14 2018-09-20 Oregon State University Peptide inhibitors targeting the neisseria gonorrhoeae pivotal anaerobic respiration factor ania
US11235056B2 (en) 2017-03-24 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glycan-masked engineered outer domains of HIV-1 gp120 and their use
EP3641806A4 (en) 2017-06-22 2021-06-23 University of Maryland, Baltimore BROAD NEUTRALIZING ANTIBODIES AGAINST HIV
BR112020007002A2 (pt) 2017-10-10 2020-11-17 Sanofi anticorpos anti-cd38 e métodos de uso
EP3755713A1 (en) 2018-02-21 2020-12-30 The United States of America, as represented by the Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 env and their use
WO2019173802A1 (en) * 2018-03-09 2019-09-12 Atreca, Inc. Anti-hiv antibodies
CN110305219B (zh) * 2018-03-27 2021-05-04 清华大学 一种包含嵌合抗原受体（car）修饰的t细胞在制备细胞药物中的用途
KR20210095998A (ko) * 2018-05-25 2021-08-04 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 항-아밀로이드 단클론성 항체를 사용하는 세균성 생물막의 박멸
WO2020010107A1 (en) 2018-07-03 2020-01-09 Gilead Sciences, Inc. Antibodies that target hiv gp120 and methods of use
CN113271974A (zh) * 2018-09-14 2021-08-17 洛克菲勒大学 抗hiv抗体10-1074变体
BR112021006558A2 (pt) 2018-10-09 2021-07-13 Sanofi proteínas de ligação triespecíficas anti-cd38, anti-cd28 e anti-cd3 e métodos de uso para o tratamento de infecção viral
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
US11795210B2 (en) 2019-07-16 2023-10-24 Gilead Sciences, Inc. HIV vaccines and methods of making and using
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
JP2023509881A (ja) 2019-12-24 2023-03-10 カルナバイオサイエンス株式会社 ジアシルグリセロールキナーゼ調節化合物
TW202146463A (zh) * 2020-03-05 2021-12-16 法商賽諾菲公司 蛋白酶加工的分子
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
EP4153181A1 (en) 2020-05-21 2023-03-29 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
CA3186054A1 (en) 2020-08-07 2022-02-10 Daniel H. BYUN Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
AU2021333577A1 (en) 2020-08-25 2023-03-30 Gilead Sciences, Inc. Multi-specific antigen binding molecules targeting HIV and methods of use
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN116437958A (zh) 2020-11-11 2023-07-14 吉利德科学公司 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CR20230585A (es) 2021-06-23 2024-02-19 Gilead Sciences Inc Compuestos Moduladores de Diacilglicerol Quinasa.
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
WO2023019019A2 (en) * 2021-08-13 2023-02-16 Abwiz Bio, Inc. Humanization, affinity maturation, and optimization methods for proteins and antibodies
CA3235937A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
US20230203071A1 (en) 2021-12-03 2023-06-29 Zhimin Du Therapeutic compounds for hiv virus infection
TW202342447A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
WO2023158505A1 (en) * 2022-02-16 2023-08-24 Prothione Llc Compositions and methods for the treatment of human immunodeficiency virus
WO2023192827A1 (en) 2022-03-26 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific antibodies to hiv-1 env and their use
WO2023192881A1 (en) 2022-03-28 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024006982A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024076915A1 (en) 2022-10-04 2024-04-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5215913A (en) 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
IL89567A0 (en) 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
US5445960A (en) * 1988-03-31 1995-08-29 The Arizona Board Of Regents On Behalf Of The University Of Arizona Monoclonal antibodies specific for HIV and hybridomas for their production
EP0361341A3 (en) * 1988-09-28 1991-07-03 Miles Inc. Therapeutics for aids based on inhibitors of hiv protease
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ATE175997T1 (de) 1991-08-10 1999-02-15 Medical Res Council Behandlung von zellpopulationen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
ATE207760T1 (de) 1993-05-07 2001-11-15 Akzo Nobel Nv Hiv immunogene komplexe
EP1241264A1 (en) 1994-12-02 2002-09-18 Chiron Corporation Monoclonal antibodies to colon cancer antigen
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
DE60139690D1 (de) 2000-07-03 2009-10-08 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
WO2002068649A2 (en) 2001-01-31 2002-09-06 Curagen Corporation Proteins and nucleic acids encoding same
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
JP2004538324A (ja) 2001-08-03 2004-12-24 メディカル リサーチ カウンシル 細胞内抗体
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
WO2003044036A1 (en) 2001-11-19 2003-05-30 Applied Molecular Evolution, Inc. Tumor specific monoclonal antibodies
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
WO2003070752A2 (en) 2002-02-20 2003-08-28 Dyax Corporation Mhc-peptide complex binding ligands
US20030232387A1 (en) 2002-06-14 2003-12-18 Millennium Pharmaceuticals, Inc. Antibodies that bind alphaE integrin
GB0313132D0 (en) 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
US7824681B2 (en) 2005-08-16 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services Human monoclonal antibodies that specifically bind IGF-II
CN101506358B (zh) * 2006-05-15 2013-07-17 免疫医学股份有限公司 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物
JP4895727B2 (ja) * 2006-08-28 2012-03-14 シスメックス株式会社 抗ｈｉｖ抗体検出試薬、試薬キット、試薬の製造方法、及び抗ｈｉｖ抗体の検出方法
RS56743B1 (sr) * 2007-08-21 2018-03-30 Amgen Inc Humani c-fms antigen vezujući proteini
US8092804B2 (en) * 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP2098536A1 (en) 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
EP2281845B1 (en) 2008-04-25 2020-09-02 Kyowa Kirin Co., Ltd. Stable polyvalent antibody
TW201022288A (en) 2008-06-30 2010-06-16 Novo Nordisk As Anti-human interleukin-20 antibodies
DK2435568T3 (da) 2009-05-29 2014-09-08 Morphosys Ag Samling af syntetiske antistoffer til behandling af sygdom
EA023179B1 (ru) 2009-08-13 2016-05-31 Круселл Холланд Б.В. Антитела против респираторного синцитиального вируса (pcb) и способы их применения
EP2480572B1 (en) 2009-09-25 2019-01-30 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 and their use
WO2012154312A1 (en) * 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
BR112013029550A2 (pt) * 2011-05-17 2022-04-19 California Inst Of Techn Anticorpos neutralizantes de vírus de imunodeficiência humana e métodos de uso dos mesmos
US9890207B2 (en) * 2011-07-25 2018-02-13 California Institute Of Technology Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120
US9493549B2 (en) * 2011-07-25 2016-11-15 The Rockefeller University Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth
CN104271597B (zh) 2011-12-08 2018-05-25 美国政府(由卫生和人类服务部的部长所代表) Hiv-1的中和抗体及其用途
LT2908912T (lt) * 2012-10-18 2020-09-25 The Rockefeller University Plačiai neutralizuojantys anti-živ antikūnai
WO2016014484A1 (en) * 2014-07-21 2016-01-28 The Rockefeller University Combination of broadly neutralizing hiv antibodies and viral inducers

Also Published As

Publication number Publication date
JP2024001150A (ja) 2024-01-09
AU2020201993B2 (en) 2022-03-31
AU2017204563B2 (en) 2018-11-22
AU2022204340A1 (en) 2022-07-14
US10889633B2 (en) 2021-01-12
PL2710033T3 (pl) 2021-10-25
CN103797029A (zh) 2014-05-14
CA2836468C (en) 2021-05-04
US9783594B2 (en) 2017-10-10
AU2017204563A1 (en) 2017-07-27
SI2710033T1 (sl) 2021-05-31
IL229469B (en) 2020-08-31
US11634478B2 (en) 2023-04-25
EP2710033A4 (en) 2015-04-22
IL276182A (en) 2020-09-30
JP2020202827A (ja) 2020-12-24
EA032929B1 (ru) 2019-08-30
BR112013029550A2 (pt) 2022-04-19
IL229469A0 (en) 2014-01-30
JP6720242B2 (ja) 2020-07-08
LT2710033T (lt) 2021-06-10
EP3865507A1 (en) 2021-08-18
JP6323718B2 (ja) 2018-05-16
CN106432484A (zh) 2017-02-22
CN116948019A (zh) 2023-10-27
US20140328862A1 (en) 2014-11-06
WO2012158948A1 (en) 2012-11-22
IL295205A (en) 2022-10-01
JP2014516527A (ja) 2014-07-17
EP2710033B1 (en) 2021-01-20
PT2710033T (pt) 2021-03-11
AU2012255266B2 (en) 2017-05-25
IL276182B (en) 2022-09-01
CN106432484B (zh) 2020-10-30
HUE053545T2 (hu) 2021-07-28
EP2710033A1 (en) 2014-03-26
CN103797029B (zh) 2016-08-17
CN112225798A (zh) 2021-01-15
MX358099B (es) 2018-08-06
US20180079800A1 (en) 2018-03-22
CN112225798B (zh) 2023-07-18
DK2710033T3 (da) 2021-03-08
JP7368812B2 (ja) 2023-10-25
CA2836468A1 (en) 2012-11-22
EA201391713A1 (ru) 2014-07-30
CY1124043T1 (el) 2022-05-27
AU2019200972B2 (en) 2020-04-16
ES2895523T3 (es) 2022-02-21
AU2020201993A1 (en) 2020-04-09
AU2019200972A1 (en) 2019-02-28
JP7076721B2 (ja) 2022-05-30
US20210230254A1 (en) 2021-07-29
JP2022115945A (ja) 2022-08-09
MX2013013360A (es) 2014-09-22
EA201990685A1 (ru) 2019-12-30
JP2018161126A (ja) 2018-10-18
AU2012255266A1 (en) 2013-12-19
US20230365661A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
HRP20210375T1 (hr) Virus ljudske imunodeficijencije neutraliziranja antitijela i postupci njegova korištenja
HRP20201975T1 (hr) Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
AU2018346978B2 (en) Anti-respiratory syncytial virus antibodies, methods of their generation and use
TWI659968B (zh) 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
HRP20201505T1 (hr) Široko neutralizirajuća anti-hiv protutijela
ES2662519T3 (es) Anticuerpos neutralizantes contra el virus de la gripe A y usos de estos
HRP20201031T1 (hr) Anti-ctla-4 protutijela i postupci njihove upotrebe
HRP20160632T1 (hr) Vezivne molekule specifične za rsv i sredstva za njihovu proizvodnju
HRP20170568T1 (hr) Protutijela anti-ox40 i postupci za njihovu uporabu
EA038993B1 (ru) Человеческие антитела к гликопротеину вируса эбола
TW201632548A (zh) 流行性感冒病毒血球凝集素之人類抗體
CN106459196A (zh) 抗体、用途和方法
RU2668802C2 (ru) Антитела, используемые для пассивной вакцинации против гриппа
CA3040886A1 (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
JP2010502207A5 (hr)
HRP20220918T1 (hr) Anti-transtiretinska antitijela
RU2017107773A (ru) Антитела, специфичные к ммр9
RU2013102073A (ru) Антитела, подходящие для пассивной иммунизации против гриппа
CA3040893A1 (en) Anti-respiratory syncytial virus antibodies, and methods of their generation and use
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
RU2020100073A (ru) Нейтрализующие антитела к вирусу гриппа b и пути их применения
RU2010126598A (ru) Применение человеческого антитела, способного нейтрализовать вирус гепатита в, для профилактики или лечения инфекции вирусом гепатита в
RU2016141285A (ru) Биспецифические антигенсвязывающие полипептиды
JP7372925B2 (ja) インフルエンザヘマグルチニンに対するヒト抗体
CN114957479B (zh) 抗H1N1流感病毒双特异性中和抗体Bis-Hu11-1及其应用